ALTER-DOMUS
Alter Domus, a leading provider of integrated solutions for the alternative investment industry, today announced it has appointed Gus Harris, Head of AD Data & Analytics, to its Group Executive Board (GEB) where he will continue to report to Doug Hart, Chief Executive Officer.
In his current role, Gus leads Alter Domus’ data and analytics products strategy and team, developing new data assets and offerings to provide value-add solutions to alternatives market participants, including risk managers, investment managers, analysts and support functions at investor and asset manager clients. The team will help clients bring their data into a modern technology-enabled environment, allowing them to develop a competitive edge in their ability to efficiently generate meaningful and timely insights from their most crucial data sets.
As an extension to our data and analytics efforts, Gus is overseeing the development of proprietary applications into Software-as-a-Service (SaaS) products, which will further expand Alter Domus’ reach into the middle and front offices of their expanding client base. Early product development has focused on solutions which improve operational governance and efficiency for clients to more effectively risk-manage, monitor and grow their alternatives portfolios. The team has lined up several clients, including new clients, and strategic partnerships to accelerate their go-to-market and will have several newly built products by year-end.
Since joining Alter Domus last October, Gus has hired a world-class team to oversee the firm’s growth in this important area. The seasoned team, which has extensive experience building similar solutions for large financial institutions globally, brings together significant capabilities around modern big data, data science, technology, and product management disciplines. Team members have honed their skills at, and joined Alter Domus directly from, reputable institutions such as Amazon Web Services, Morgan Stanley, Moody’s Analytics, KPMG, and other established multinational organizations.
“Technology has been an integral part of the backbone of Alter Domus’ offering to clients, and Gus has brought an innovative and forward-thinking vision to our data and analytics services. Clients are under increasing pressure to better manage and exploit data, which makes Gus’ voice and perspective at a group executive level particularly important,” said Doug Hart . “Gus brings a strong sense of leadership, collegiality, and considerable expertise to our leadership team, key traits which have helped to catalyze his team’s growth and offering in a relatively short period of time.”
“I am proud to join Alter Domus’ group executive board, and I look forward to partnering with this talented and dynamic group of executive leaders. Alter Domus’ data and analytics team, which is comprised of seasoned and proven industry professionals, is undergoing tremendous growth and is already engaging with leading general and limited partners in the private equity, private debt – including CLO managers and investors – and commercial real estate sectors on complex and important projects,” said Gus Harris . “This reflects the increasingly important role that data and analytics will play in the future of our business, and the alternative investment industry as a whole. As the marketplace matures, demand for ‘better data’ will only continue to grow, and we are extremely well-positioned to support the market on this transformational journey. With technology running across the spectrum of our data solutions – from collection, to analytics, to delivery – we’re thrilled to be helping clients define the standards that will set their business on a solid foundation for sustainable future growth.”
Prior to joining Alter Domus in September 2021, Gus was a founding executive of Moody’s Analytics where he helped build several flagship products and services including Moody’s structured-finance products, ESG data and research services, Moody’s DataHub (DaaS), and other SaaS tools. Gus is a CPA and CFA charter holder and completed advanced degrees in finance from Columbia Business School, risk and statistics from New York University’s Stern School of Business, and technology from Pace University.
About Alter Domus
Alter Domus is a leading provider of integrated solutions, serving private equity, real assets and debt capital markets sectors with more than 3,600 employees across 36 offices globally. Solely dedicated to alternatives, Alter Domus offers fund administration, corporate services, depositary services, capital administration, transfer pricing, domiciliation, management company services, loan administration, agency services, trade settlement and CLO manager services. Find out more at www.alterDomus.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220719005226/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Scoring Big With Fans: Balchem Spotlights the Power of Vitamin K2 at FC Bayern Women’s Season Opener18.9.2025 14:33:00 CEST | Press release
Balchem, a leading global manufacturer of specialty ingredients for human nutrition and health – and official partner of FC Bayern (FCB) Women’s football team - has launched its first ever direct-to-consumer initiative, showcasing the power of vitamin K2 to FCB fans. The company promoted its K2VITAL™ brand with an exhibition stand at the Allianz Arena in Munich, during the opening game of the Bundesliga (German football league) on 6 September. This initiative is part of Balchem’s latest marketing strategy, which aims to raise consumer awareness of the health benefits vitamin K2 has to offer, bridging the gap between B2B and B2C markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918950889/en/ Balchem Spotlights The Power of Vitamin K2 at FC Bayern Women’s Season Opener Co-Branded K2 Health Vitamins Hit the Pitch The opening event of the season provided a unique platform for Balchem to promote K2VITAL™, a patented, typ
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy18.9.2025 14:30:00 CEST | Press release
- CASGEVY is the first, and only, gene editing therapy approved for the treatment of transfusion-dependent beta thalassemia (TDT) and sickle cell disease (SCD) in Europe -- Italy has the largest population of people living with TDT in Europe- Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with the Italian Medicines Agency (AIFA) for eligible transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). “Today is a turning point for eligible people in Italy living with transfusion-dependent beta thalassemia and sickle cell disease, two life-shortening diseases with limited treatment options,” said Ludovic Fenaux, Senior Vice President, Vertex International. “Italy has the largest TDT population in Europe, which underscores the importance of this agreement. We appreciate the collaboration with AIFA to recognize the value a one-time transformati
European DataWarehouse Appoints Nigel Batley as Executive Director of Its UK Subsidiary18.9.2025 12:41:00 CEST | Press release
European DataWarehouse Ltd. (EDW Ltd.) the UK subsidiary of European DataWarehouse GmbH, today announced the appointment of Nigel Batley as Executive Director. Mr. Batley succeeds Markus Schaber, who will retire from the role after serving as Executive Director since 2020. With nearly 40 years of experience in the financial services industry, Mr. Batley brings extensive expertise in asset-backed finance. He spent more than 30 years at HSBC, where he held senior positions including Global Head of Structured Finance, before taking on advisory and leadership roles in the securitisation market. Markus Schaber, outgoing Executive Director of EDW Ltd., will remain with the company as Senior Advisor. He commented: “It has been a privilege to lead European DataWarehouse in the UK and contribute to the development of greater transparency in European securitisation markets. I am confident that Nigel’s deep industry knowledge and leadership will strengthen EDW Ltd.’s mission and ensure we continu
Zycus Recognized as A Customers’ Choice in 2025 Gartner® Peer Insights™ “Voice of the Customer” for Source-to-Pay Suites18.9.2025 11:20:00 CEST | Press release
Zycus, a global leader in procurement and source-to-pay transformation, today announced it has been recognized as A Customers’ Choice in 2025 Gartner Peer Insights™ “Voice of the Customer”: Source-to-Pay Suites report. The Gartner Peer Insights report aggregates ratings and reviews from verified end users over an 18-month ending June 30, 2025. To qualify, vendors must have at least 20 eligible reviews and meet thresholds for capabilities and support. In the 2025 report, only eight vendors qualified, with Zycus placed in the Customers’ Choice quadrant — highlighting vendors rated above the market average for both Overall Experience and User Interest & Adoption. Recognition Backed by Customer Experience According to the report, Zycus achieved: 4.6 out of 5 Overall Rating, based on 67 peer reviews as of June 30, 2025. 95% willingness to recommend score – reflecting customer trust and satisfaction. Ratings across Product Capabilities, Sales Experience, Deployment, and Support, each above 4
Neumirna Therapeutics Appoints Ellen K. Donnelly as Chief Executive Officer18.9.2025 11:00:00 CEST | Press release
Neumirna Therapeutics, a biotechnology company developing RNA-based therapies for neurological diseases, today announced the appointment of Ellen K. Donnelly, Ph.D. as Chief Executive Officer. Ellen brings more than 20 years of leadership in neuroscience and rare diseases, spanning both global pharmaceutical companies and innovative biotech firms. She joins Neumirna from her role as CEO of Abliva AB, recently acquired by Pharming Group, and has previously led Modus Therapeutics and Souvien Therapeutics. Earlier in her career, Ellen spent nearly a decade at Pfizer Inc., where she held leadership roles in neuroscience research, clinical operations, portfolio management, and strategy. She holds a Ph.D. in Pharmacology & Neuroscience from Yale University. "Ellen combines scientific expertise with proven leadership in both biotech and pharma," said Luis Pareras, Chairman of the Board at Neumirna. "The Board is confident that under her guidance, Neumirna will continue to translate our innova
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom